Western blot analysis of the tumor tissues confirmed that HER2 protein expression was reduced in both the pyrotinib and T-Dxd single-agent groups compared to the control group, though the combination therapy group exhibited a significantly greater reduction in HER2 protein expression than in the other groups (Fig. 5f). The gene discussed is ERBB2; the disease is neoplasm.